Abstract
Ten to fifteen percent of patients with metastatic testis cancer (mGCT) will develop chemorefractory disease of which about 50% will die. We report on the integration of next generation sequencing in daily clinical practice to identify druggable mutations in metastatic lesions of 3 patients with mGCT. Mutational analysis revealed KIT D820G, TP53, and NPM1 mutations as well as mismatch repair deficiency with loss of MSH2 and MSH6 proteins so that targeted therapy with sunitinib (n = 2) or pembrolizumab (n = 1) was initiated resulting in remarkable partial remissions for 9, 12+, and 15 months.
References
1.
Testicular cancer. EAU guidelines 2020. Available from: https://uroweb.org/guideline/testicular-cancer
.2.
Oing
C
, Kollmannsberger
C
, Oechsle
K
, Bokemeyer
C
. Investigational targeted therapies for the treatment of testicular germ cell tumors
. Expert Opin Investig Drugs
. 2016
;25
(9
):1033
–43
. .3.
Tsimberidou
AM
, Fountzilas
E
, Nikanjam
M
, Kurzrock
R
. Review of precision cancer medicine: evolution of the treatment paradigm
. Cancer Treat Rev
. 2020
;86
:102019
. .4.
Kern
SQ
, Einhorn
LE
, Adra
N
. Genomic analysis for potential targetable mutations in relapsed and refractory germ cell tumors
. Abstract #407, GU-ASCO 2020.5.
Subbiah
V
, Meric-Bernstam
F
, Mills
GB
, Shaw
KR
, Bailey
AM
, Rao
P
, et al. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to sunitinib (sutent®) a VEGFR2/PDGFRβ/c-kit/FLT3/RET/CSF1R inhibitor in a phase II trial
. J Hematol Oncol
. 2014
;7
:52
–60
.6.
Matheson
CJ
, Backos
DS
, Reigan
P
. Targeting WEE1 kinase in cancer
. Trends Pharmacol Sci
. 2016
;37
(10
):872
–81
. .7.
Yu
J
, Li
Y
, Zhang
D
, Wan
D
, Jiang
Z
. Clinical implications of recurrent gene mutations in acute myeloid leukemia
. Exp Hematol Oncol
. 2020
;9
:4
–12
. .8.
Adra
N
, Einhorn
LH
, Althouse
SK
, Ammakkanavar
NR
, Musapatika
D
, Albany
C
, et al. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a hoosier cancer research network study GU14-206
. Ann Oncol
. 2018
;29
(1
):209
–14
. .9.
Mego
M
, Svetlovska
D
, Chovanec
M
, Rečkova
M
, Rejlekova
K
, Obertova
J
, et al. Phase II study of avelumab in multiple relapsed/refractory germ cell cancer
. Invest New Drugs
. 2019
;37
(4
):748
–54
. .10.
Le
DT
, Durham
JN
, Smith
KN
, Wang
H
, Bartlett
BR
, Aulakh
LK
, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
. Science
. 2017
;357
(6349
):409
–13
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.